Activities of dalbavancin in vitro and in a rabbit model of experimental endocarditis due to Staphylococcus aureus with or without reduced susceptibility to vancomycin and teicoplanin

Abstract

For the treatment of rabbit endocarditis, dalbavancin given once daily (10 mg/kg of body weight for 4 days) or as a single 40-mg/kg dose was active against Staphylococcus aureus with or without reduced susceptibility to glycopeptides, as expected from its good in vitro activity, even in broth supplemented with 90% serum and given its prolonged elimination half-life.

FIG. 1.

Time-kill study of dalbavancin (DAL), vancomycin (Vanco), and teicoplanin (Teico) at various concentrations against S. aureus Lim-1 (A) and Lim-2 (B) (with or without rabbit serum) and against S. aureus 218, a teicoplanin-resistant derivative of Lim-2 (C), all in BHI broth.

FIG. 2.

Mean concentrations of dalbavancin in serum following a single intravenous injection of 10 or 40 mg/kg in uninfected rabbits. Corresponding pharmacokinetic parameters of dalbavancin following administration of 10 or 40 mg/kg are shown in the embedded table.